Table 2.
LC50, TGI, and GI50 values for canine mammary gland tumor (CMT) adenocarcinoma cells treated with ZER-NLC, ZER, DOXO.
| Concentration (μM) | Treatments | |||
|---|---|---|---|---|
| Time (h) | ZER-NLC | ZER | DOXO | |
| LC50 | 24 | 84.70 ± 8.68 | 128.68 ± 5.47 | 95.99 ± 10.54 |
| 48 | 68.61 ± 10.10 | 84.86 ± 14.30 | 19.62 ± 5.83 | |
| 72 | 84.54 ± 10.44 | 94.63 ± 10.80 | 5.89 ± 0.05 | |
|
| ||||
| TGI | 24 | 20.47 ± 10.52 | 46.22 ± 10.12 | 24.91 ± 10.88 |
| 48 | 23.52 ± 6.87 | 34.39 ± 5.87 | 4.51 ± 0.08 | |
| 72 | 27.29 ± 4.87 | 32.28 ± 1.29 | 3.93 ± 0.03 | |
|
| ||||
| GI50 | 24 | 4.12 ± 0.97 | 18.49 ± 3.63 | 4.39 ± 0.77 |
| 48 | 4.32 ± 0.71 | 11.44 ± 2.48 | 2.25 ± 0.04 | |
| 72 | 8.63 ± 1.16 | 11.36 ± 0.42 | 1.96 ± 0.02 | |
Data are mean ± SD (n=3), analyzed using one-way ANOVA and post hoc Tukeytest.
DOXO: doxorubicin; GI50: growth inhibition concentration 50; LC50: lethal concentration 50; TGI: total growth inhibition concentration; ZER: zerumbone; ZER-NLC: zerumbone-loaded nanostructured lipid carrier.